Combination therapy for bone metastases from advanced lung cancer
Treatments studied
Part of Bones, joints & muscles, Cancer clinical trials.
This trial tests adding a new drug (narlumosbart) and targeted radiation to standard chemotherapy and immunotherapy for people with advanced non-small cell lung cancer that has spread to the bones. The goal is to see if this combination works better than standard treatment alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have stage IV non-small cell lung cancer that has spread to your bones and needs radiation.
- You haven't had any previous cancer treatment (like chemotherapy, targeted therapy, or immunotherapy) for lung cancer.
- If you have adenocarcinoma (a type of lung cancer), your tumor must not have certain gene changes (EGFR, ALK, ROS-1). Squamous cell cancer doesn't need this testing.
- You must have at least one tumor that can be measured that is not in the bone.
- Your performance status is good (ECOG score of 0 or 1), meaning you are fully active or only slightly limited.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with stereotactic body radiation therapy (SBRT) for people with early-stage non-small cell lung cancer. The goal is to see if this treatment can help shrink or control the cancer before surgery.
This trial tests whether adding two newer drugs (benmelstobart and anlotinib) to chemotherapy before radiation works better than radiation alone for stage III non-small cell lung cancer that cannot be surgically removed. The goal is to improve survival and control the cancer.
This trial studies whether adding targeted radiation to the liver (small-area, high-precision radiation) can help people with stage IV non-small cell lung cancer. Participants also start standard “anti–PD-1/PD-L1” immunotherapy (with chemotherapy in some cases).
This trial is testing a combination of immunotherapy and targeted radiation for people with advanced lung cancer that has no targetable gene changes. The goal is to see if adjusting radiation based on how well the tumor responds can improve outcomes.
This trial tests a combination of a targeted chemotherapy bead injection into lung arteries, an oral anti-cancer drug, and an immunotherapy for advanced non-small cell lung cancer that has not responded to two prior treatments. It aims to see if this triple approach can help patients who have limited options left.
This trial tests a new drug called Narlumosbartmab added to standard chemotherapy for certain types of bone cancer that have eaten away at the bone and contain large, abnormal cells. It is for people who have not yet started standard treatment and whose tumors can be removed with surgery.
Hear when a new Stereotactic Body Radiation Therapy (SBRT) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.